NCT05882773 Asian Myeloproliferative Neoplasm (MPN) Registry
| NCT ID | NCT05882773 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Myeloproliferative Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-05 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-05 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old at the time of diagnosis of MPN. 2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification): 1. Polycythaemia vera 2. Essential thrombocythemia 3. Primary myelofibrosis, pre-fibrotic/early stage 4. Primary myelofibrosis, overt fibrotic stage 5. Post-polycythaemia vera myelofibrosis 6. Post-essential thrombocythaemia myelofibrosis 7. MPN-unclassifiable 3. All subjects need to provide informed consent. Exclusion Criteria: A subject will not be eligible if he/she meets any of the following criteria: 1\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
Contact & Investigator
Harinder Gill, MD
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT05882773 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloproliferative Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05882773 currently recruiting?
Yes, NCT05882773 is actively recruiting participants. Contact the research team at gillhsh@hku.hk for enrollment information.
Where is the NCT05882773 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05882773 clinical trial?
NCT05882773 is sponsored by The University of Hong Kong. The principal investigator is Harinder Gill, MD at The University of Hong Kong. The trial plans to enroll 1,000 participants.